Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III equivalence study of KM118 versus pertuzumab with trastuzumab and docetaxel as neoadjuvant therapy for HER2-positive early or locally advanced breast cancer
CTR20230773Phase 3Active
- Sponsor
- China Resources Double-Crane Pharmaceutical
- Start
- Mar 2023
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of KM118, pertuzumab, trastuzumab and docetaxel in breast cancer, sponsored by China Resources Double-Crane Pharmaceutical. Primary endpoint: tpCR. Started Mar 2023; status: active.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20230773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230773.